These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 7876541)

  • 1. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
    J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
    Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
    Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
    Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased IgE level as a marker of host-versus-graft disease: inhibition of this HVGD with a monoclonal antibody to IL-4.
    Takai S; Tateno M; Hirano T; Kondo N; Hirose S; Yoshiki T
    Cell Immunol; 1993 Jun; 149(1):1-10. PubMed ID: 8513506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
    J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
    Abraham VS; Sachs DH; Sykes M
    J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
    Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
    J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.
    Margalit M; Ilan Y; Ohana M; Safadi R; Alper R; Sherman Y; Doviner V; Rabbani E; Engelhardt D; Nagler A
    Bone Marrow Transplant; 2005 Jan; 35(2):191-7. PubMed ID: 15558045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
    Hattori K; Hirano T; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K
    Br J Haematol; 1999 Apr; 105(1):303-12. PubMed ID: 10233398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.